RA
Resolute Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $74.2K | Buy |
+14,670
| New | +$74.2K | 0.02% | 68 |
|
|
2025
Q1 | – | Sell |
-14,670
| Closed | -$99.2K | – | 86 |
|
|
2024
Q4 | $99.2K | Hold |
14,670
| – | – | 0.02% | 77 |
|
|
2024
Q3 | $96.7K | Hold |
14,670
| – | – | 0.02% | 58 |
|
|
2024
Q2 | $110K | Hold |
14,670
| – | – | 0.03% | 51 |
|
|
2024
Q1 | $146K | Hold |
14,670
| – | – | 0.03% | 51 |
|
|
2023
Q4 | $145K | Hold |
14,670
| – | – | 0.02% | 60 |
|
|
2023
Q3 | $112K | Buy |
14,670
+3,668
| +33% | +$28.1K | 0.02% | 56 |
|
|
2023
Q2 | $82.2K | Hold |
11,002
| – | – | 0.01% | 59 |
|
|
2023
Q1 | $73.4K | Hold |
11,002
| – | – | 0.01% | 58 |
|
|
2022
Q4 | $84.8K | Hold |
11,002
| – | – | 0.01% | 54 |
|
|
2022
Q3 | $117K | Buy |
11,002
+1,834
| +20% | +$19.5K | 0.01% | 58 |
|
|
2022
Q2 | $75K | Hold |
9,168
| – | – | 0.01% | 67 |
|
|
2022
Q1 | $66K | Hold |
9,168
| – | – | ﹤0.01% | 74 |
|
|
2021
Q4 | $157K | Buy |
+9,168
| New | +$157K | ﹤0.01% | 67 |
|